A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer.
about
Prostate-specific membrane antigen as a target for cancer imaging and therapyProgress of molecular targeted therapies for prostate cancersProstate cancer relevant antigens and enzymes for targeted drug deliveryAntibody Drug Conjugates: Preclinical ConsiderationsTheragnostic ultrasound using microbubbles in the treatment of prostate cancerDrug delivery systems in urology--getting "smarter".Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: implications for novel intraoperative PSMA-based fluorescent imaging techniquesOxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Prostate-specific membrane antigen-based therapeutics.Targeted therapies for prostate cancer.In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer.Cancer-cell-phenotype-dependent differential intracellular trafficking of unconjugated quantum dots.Anticancer carrier-linked prodrugs in clinical trials.Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigenBispecific small molecule-antibody conjugate targeting prostate cancer.Serially heterotransplanted human prostate tumours as an experimental modelTargeting the prostate-specific membrane antigen for prostate cancer therapy.Jekyll and Hyde: the role of the microenvironment on the progression of cancer.Recent developments in prostate cancer biomarker research: therapeutic implications.Antibody-targeted nanoparticles for cancer therapy.Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancerMolecular engineering of antibodies for therapeutic and diagnostic purposes.Pharmacokinetic considerations for antibody drug conjugates.An overview of targeted cancer therapy.Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancerProstate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer.Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancerTargeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives.Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.Charge-based analysis of antibodies with engineered cysteines: from multiple peaks to a single main peak.Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
P2860
Q26799439-637A05AA-CA40-422E-AD6E-3689E657EBF3Q26823014-BE6615D5-EDCF-4691-AF92-BAC62A521824Q27013843-54649C93-9723-427B-B4D5-41233928058FQ27022321-96AEBB39-CD13-402D-B07A-79882E619C2BQ28067216-B5BF1CA6-F922-46D9-B835-3A6BC23F59E0Q30478170-9B3F5969-30DA-40BA-A6E2-295028218E38Q33922507-A9B74586-84F2-4331-A2FB-89F1D90FBE5AQ34162875-D69904E2-D5E9-4C72-8D25-E6883505B477Q34655256-54093397-D873-456C-818B-F1DBF15E7AEFQ35132944-EE06C509-15CE-47A1-8BB0-CDE243E9D317Q36150842-1AA8DA7E-D48C-4CEF-964A-323D61B49D83Q36407249-768CBF87-7462-44DC-B166-E118A5AC863DQ36422280-55D4F58E-FAEF-44C3-891D-7A0408AE03BDQ36861603-BE753321-B87F-4613-8CA4-FFEDFB177FADQ37183709-59D08BC3-489B-4576-A4D3-55AABAE9C9A3Q37276578-BED0096F-E5C9-4C20-A929-4ED76FC68679Q37310963-4D72991A-48BC-4C14-8EB4-B1E5AF93A584Q37773273-B628671A-0914-4394-B8DE-E2933771523FQ37815128-D9F97A92-46ED-496F-8BCB-74C0A7F17144Q37827186-ECFF3CD2-DD99-4946-8718-392E8EF74E3DQ37851969-5F3FA0F0-5AA0-43E4-9CD2-4D0D96A8CAC5Q37854644-0D8E8034-CA3C-4670-981C-B0AC2487011FQ37972920-364A48A3-7D67-4F67-9A2E-FD287B855F67Q38017581-E946B405-3798-40F5-B911-501B4E591EF2Q38022192-D36451CE-5A32-4FA3-AF87-646562AB02ADQ38650558-EFC7A2B5-E8CC-47FB-803B-FB96B55830F2Q38773250-9715020A-406B-4B9F-B03F-3880AC90DD3CQ38982670-A34277EC-B728-4630-9D68-E138F4EA89FBQ39070519-89B81D6C-F0F4-4F0E-8119-8D0D0466553BQ40125422-232005BF-3C40-4C9A-9A48-286CA0277B40Q40189253-12B5D910-9BBD-442A-95C2-52D485504914Q40371330-C168B823-8D53-4F9D-B9CE-EE24BEC83990Q41600550-1BA06658-AB4B-4FAC-B7B6-2D0976F738F8Q42957188-2A04870D-134B-42BE-8A0B-734095B1CA7DQ44895959-B39C6201-B684-42F3-95E8-B6FDB97979E3Q44994966-CA396E58-DD7D-4CDD-8AB4-A0FE1D9187A9Q49920174-37912075-DD84-409D-A118-1460EF2EC256Q51743830-8560B5A6-56A0-4FE9-A93D-7C295212D609
P2860
A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
A prostate-specific membrane a ...... treatment of prostate cancer.
@en
A prostate-specific membrane a ...... treatment of prostate cancer.
@nl
type
label
A prostate-specific membrane a ...... treatment of prostate cancer.
@en
A prostate-specific membrane a ...... treatment of prostate cancer.
@nl
prefLabel
A prostate-specific membrane a ...... treatment of prostate cancer.
@en
A prostate-specific membrane a ...... treatment of prostate cancer.
@nl
P2093
P1433
P1476
A prostate-specific membrane a ...... treatment of prostate cancer.
@en
P2093
Mark Milton
Matthew D Silva
Michael D Henry
Peter J Worland
Shenghua Wen
Sudeep Chandra
P304
P356
10.1158/0008-5472.CAN-04-1722
P407
P577
2004-11-01T00:00:00Z